Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 5/20 | 0.53 |
| ▸ | NPY1R | P25929 | 4/20 | 0.53 |
| ▸ | NPY2R | P49146 | 3/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31343363 | 1.00 | NPY4R (0.53) | NPY4RNPY1RNPY2RERAP2ERAP1 | |
| SCHEMBL31343405 | 1.00 | NPY4R (0.53) | NPY4RNPY1RNPY2RERAP2ERAP1 | |
| SCHEMBL31343323 | 1.00 | NPY4R (0.53) | NPY4RNPY1RNPY2RERAP2ERAP1 | |
| Sinapultide SCHEMBL29360133 | 1.00 | NPY4R (0.53) | NPY4RNPY1RNPY2RERAP2ERAP1 | |
| SCHEMBL31343172 | 0.99 | NPY4R (0.52) | NPY4RNPY1RNPY2RERAP2ERAP1 | |
| SCHEMBL29404079 | 0.99 | NPY4R (0.52) | NPY4RNPY1RNPY2RERAP2ERAP1 | |
| SCHEMBL29630471 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RERAP2ERAP1 | |
| SCHEMBL29682467 | 0.96 | NPY4R (0.52) | NPY4RNPY1RNPY2RERAP2ERAP1 | |
| SCHEMBL31018772 | 0.95 | NPY4R (0.50) | NPY4RNPY1RNPY2RERAP2ERAP1 | |
| SCHEMBL31018773 | 0.95 | NPY4R (0.50) | NPY4RNPY1RNPY2RERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727418-B1 | SURFACTANT FORMULATIONS FOR INHALATION | MERZ PHARMACEUTICALS LLC (US) | 2026-04-08 | — | — | EP | claimed |
| US-12589161-B2 | PEGylated synthetic KL4 peptide, compositions and methods thereof | THE UNIVERSITY OF HONG KONG (CN) | 2026-03-31 | — | — | US | claimed |
| US-20250288516-A1 | Surfactant Formulations for Inhalation | MERZ PHARMACEUTICALS LLC (US) | 2025-09-18 | — | — | US | claimed |
| US-20250262150-A1 | Surfactant Formulations for Inhalation | MERZ PHARMACEUTICALS LLC (US) | 2025-08-21 | — | — | US | claimed |
| CN-120000688-A | Atomization inhalation composition based on stem extracellular vesicles, and preparation method and application thereof | 山东杰凯生物科技有限公司 | 2025-05-16 | — | — | CN | claimed |
| EP-3996686-B1 | PEGYLATED SYNTHETIC KL4 PEPTIDE, COMPOSITIONS AND METHODS THEREOF | UNIV HONG KONG (CN) | 2025-03-26 | — | — | EP | claimed |
| CN-114206906-B | PEGylated synthetic KL4 peptides, compositions and methods thereof | 香港大学 | 2024-02-20 | — | — | CN | claimed |
| US-20230172869-A1 | A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-08 | — | — | US | claimed |
| CN-114213546-B | VEGFR-targeted cleavage peptide conjugate and application thereof | 华中科技大学同济医学院附属协和医院 | 2023-05-05 | — | — | CN | claimed |
| EP-4138856-A1 | A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-01 | — | — | EP | claimed |
| EP-1638567-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA Pharma AG (DE) | 2006-03-29 | — | — | EP | claimed |
| WO-2006013183-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A TNF-DERIVED PEPTIDE | ALTANA PHARMA AG (DE) | 2006-02-09 | — | — | WO | claimed |
| WO-2005021037-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE2 INHIBITOR | ALTANA PHARMA AG (DE) | 2005-03-10 | — | — | WO | claimed |
| EP-1357928-A4 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2004110450-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA PHARMA AG (DE) | 2004-12-23 | — | — | WO | claimed |
| US-20040132967-A1 | Mimetic peptide comprised of terminal amino acid sequences of surfactant protein b (SP-B) and dipalmitoylphosphatidylcholine for use in treatment of respiratory system disorder | WALTHER FRANS J (US) | 2004-07-08 | — | — | US | claimed |
| EP-1357928-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | New River Pharmaceuticals Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | claimed |
| US-6436970-B1 | POWDERS COMPRISING HETEROCYCLIC IMINES, PROTEIN-B AND/OR-C, USED FOR THE PROPHYLAXIS OF INFANT OR ADULT RESPIRATORY DISTRESS SYNDROME | BYK GULDEN LOMBERG CHEMISCHE FEBRIK GMBH (DE) | 2002-08-20 | — | — | US | claimed |
| US-6031075-A | AMINO ACID SEQUENCE OF SYNTHESIZED ISOLATED ALVEOLAR SURFACTANT PROTEIN-B PRODUCED BY CLEAVING FUSION PROTEIN | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2000-02-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589161-B2 | PEGylated synthetic KL4 peptide, compositions and methods thereof | KLK14, KLK4, KLK13 | NPY4R 56/4885NPY1R 445/4885NPY2R 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.